Abstract
Pegfilgrastim, a long-acting G-CSF, reduces the risk of chemotherapy-induced FN. Results from the previously reported multicenter, prospective, observational study demonstrated the utility of pegfilgrastim (Neulasta OBI®) in decreasing FN risk and improving adherence and compliance to G-CSF support in cancer patients treated with myelosuppressive chemotherapy. Results of a subgroup analysis in breast cancer patients are reported here.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
